Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 114, Issue 24, Pages E4782-E4791
Publisher
Proceedings of the National Academy of Sciences
Online
2017-05-23
DOI
10.1073/pnas.1703683114
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Drugging DNA repair
- (2016) Stephen P. Jackson et al. SCIENCE
- Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors
- (2015) Amita Patnaik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting DNA damage response in cancer therapy
- (2014) Noriko Hosoya et al. CANCER SCIENCE
- Targeting DNA repair pathways for cancer treatment: what’s new?
- (2014) Mark R Kelley et al. Future Oncology
- Downmodulation of Tumor Suppressor p53 by T Cell Receptor Signaling Is Critical for Antigen-Specific CD4+ T Cell Responses
- (2014) Masashi Watanabe et al. IMMUNITY
- Targeting Apoptosis Pathways for New Cancer Therapeutics
- (2013) Longchuan Bai et al. Annual Review of Medicine
- Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
- (2013) Takashi Seto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Wee1 kinase as a target for cancer therapy
- (2013) Khanh Do et al. CELL CYCLE
- A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis
- (2013) M Kracikova et al. CELL DEATH AND DIFFERENTIATION
- Mitosis and apoptosis: how is the balance set?
- (2013) Caroline H Topham et al. CURRENT OPINION IN CELL BIOLOGY
- Eliminating Encephalitogenic T Cells without Undermining Protective Immunity
- (2013) J. P. McNally et al. JOURNAL OF IMMUNOLOGY
- Etoposide Selectively Ablates Activated T Cells To Control the Immunoregulatory Disorder Hemophagocytic Lymphohistiocytosis
- (2013) T. S. Johnson et al. JOURNAL OF IMMUNOLOGY
- Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
- (2013) A. D. Guertin et al. MOLECULAR CANCER THERAPEUTICS
- Lessons learned and concepts formed from study of the pathogenesis of the two negative-strand viruses lymphocytic choriomeningitis and influenza
- (2013) Michael B. A. Oldstone PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells
- (2012) H. J. Landau et al. MOLECULAR CANCER THERAPEUTICS
- The Role of the Apoptotic Machinery in Tumor Suppression
- (2012) A. R. D. Delbridge et al. Cold Spring Harbor Perspectives in Biology
- Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol
- (2011) H. Trottestam et al. BLOOD
- How I treat hemophagocytic lymphohistiocytosis
- (2011) M. B. Jordan et al. BLOOD
- Translational approaches targeting the p53 pathway for anti-cancer therapy
- (2011) Frank Essmann et al. BRITISH JOURNAL OF PHARMACOLOGY
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
- (2011) Cris S Constantinescu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Interleukin-13 (IL-13)/IL-13 Receptor α1 (IL-13Rα1) Signaling Regulates Intestinal Epithelial Cystic Fibrosis Transmembrane Conductance Regulator Channel-dependent Cl−Secretion
- (2011) David Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Hemophagocytosis causes a consumptive anemia of inflammation
- (2011) Erin E. Zoller et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
- (2011) J. M. Kreahling et al. MOLECULAR CANCER THERAPEUTICS
- MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil
- (2010) Hiroshi Hirai et al. CANCER BIOLOGY & THERAPY
- Primary immunodeficiencies associated with DNA-repair disorders
- (2010) Mary A. Slatter et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Dendritic Cells Support Homeostatic Expansion of Foxp3 + Regulatory T Cells in Foxp3.LuciDTR Mice
- (2010) Janine Suffner et al. JOURNAL OF IMMUNOLOGY
- The Cell Cycle Time of CD8+ T Cells Responding In Vivo Is Controlled by the Type of Antigenic Stimulus
- (2010) Heesik Yoon et al. PLoS One
- Comprehensive analyses and characterization of haemophagocytic lymphohistiocytosis in Vietnamese children
- (2009) Lam T. My et al. BRITISH JOURNAL OF HAEMATOLOGY
- Modes of p53 Regulation
- (2009) Jan-Philipp Kruse et al. CELL
- Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
- (2009) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
- (2008) S. D. Zabludoff et al. MOLECULAR CANCER THERAPEUTICS
- FOUR NEW CASES OF THERAPY-RELATED ACUTE PROMYELOCYTIC LEUKEMIA AFTER MITOXANTRONE
- (2008) I. Bosca et al. NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search